The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene.
The muscle specific ubiquitin E3 ligase MuRF1 has been implicated as a key regulator of muscle atrophy under a variety of conditions, such as during synthetic glucocorticoid treatment. FOXO class transcription factors have been proposed as important regulators of MuRF1 expression, but its regulation by glucocorticoids is not well understood. The MuRF1 promoter contains a near-perfect palindromic glucocorticoid response element (GRE) 200 base pairs upstream of the transcription start site. The GRE is highly conserved in the mouse, rat, and human genes along with a directly adjacent FOXO binding element (FBE). Transient transfection assays in HepG2 cells and C(2)C(12) myotubes demonstrate that the MuRF1 promoter is responsive to both the dexamethasone (DEX)-activated glucocorticoid receptor (GR) and FOXO1, whereas coexpression of GR and FOXO1 leads to a dramatic synergistic increase in reporter gene activity. Mutation of either the GRE or the FBE significantly impairs activation of the MuRF1 promoter. Consistent with these findings, DEX-induced upregulation of MuRF1 is significantly attenuated in mice expressing a homodimerization-deficient GR despite no effect on the degree of muscle loss in these mice vs. their wild-type counterparts. Finally, chromatin immunoprecipitation analysis reveals that both GR and FOXO1 bind to the endogenous MuRF1 promoter in C(2)C(12) myotubes, and IGF-I inhibition of DEX-induced MuRF1 expression correlates with the loss of FOXO1 binding. These findings present new insights into the role of the GR and FOXO family of transcription factors in the transcriptional regulation of the MuRF1 gene, a direct target of the GR in skeletal muscle.
Waddell
David S
DS
Department of Neurobiology, Physiology, and Behavior, University of California, Davis, California 95616, USA.
Baehr
Leslie M
LM
van den Brandt
Jens
J
Johnsen
Steven A
SA
Reichardt
Holger M
HM
Furlow
J David
JD
Bodine
Sue C
SC
D000818:Animals; D015152:Blotting, Northern; D002478:Cells, Cultured; D002843:Chromatin / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors / Q000235:genetics* / Q000502:physiology*; D017930:Genes, Reporter / Q000235:genetics; D006801:Humans; D047468:Immunoprecipitation; D008156:Luciferases / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D009124:Muscle Proteins / Q000235:genetics / Q000502:physiology*; D009133:Muscular Atrophy / Q000235:genetics* / Q000473:pathology*; D010957:Plasmids / Q000235:genetics; D011965:Receptors, Glucocorticoid / Q000235:genetics* / Q000502:physiology*; D000070584:Tripartite Motif Proteins; D044767:Ubiquitin-Protein Ligases / Q000235:genetics / Q000502:physiology*
D002843:Chromatin; C085126:FOXO1 protein, human; D000071161:Forkhead Box Protein O1; D051858:Forkhead Transcription Factors; D009124:Muscle Proteins; D011965:Receptors, Glucocorticoid; D000070584:Tripartite Motif Proteins; D003907:Dexamethasone; D008156:Luciferases; C440908:TRIM63 protein, human; D044767:Ubiquitin-Protein Ligases